BFM
EWTX icon

Boothbay Fund Management’s Edgewise Therapeutics EWTX Stock Holding History

Boothbay Fund Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,700
Closed -$174K – 2079
2025
Q3 		$174K Buy
+10,700
New +$152K ﹤0.01% 1670

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Boothbay Fund Management's EWTX Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in Edgewise Therapeutics (EWTX) in Q2 2026: 82,734 shares worth $3.36M. The stake represents 0.04% of the portfolio and ranks #482 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in EWTX as recently as Q1 2025.

Boothbay Fund Management first reported a position in EWTX in Q3 2022 and has held it in 4 quarters since. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Boothbay Fund Management held 82,734 shares of Edgewise Therapeutics worth $3.36M as of Q2 2026.
  • Edgewise Therapeutics was a new Boothbay Fund Management position in Q2 2026.
  • Edgewise Therapeutics made up 0.04% of Boothbay Fund Management's portfolio in Q2 2026, its #482 holding.
  • Boothbay Fund Management first reported a position in Edgewise Therapeutics in Q3 2022 and has held it in 4 quarters since.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.